Daily Newsletter

27 November 2023

Daily Newsletter

27 November 2023

SciSparc begins clinical trial of ASD therapy

The SCI-210 therapy combines cannabidiol and SciSparc's Palmitoylethanolamide, designed to reduce autism spectrum disorder (ASD) symptoms.

RanjithKumar Dharma November 27 2023

SciSparc has commenced the clinical trial of its new therapy, SCI-210, to treat ASD symptoms in children.

ASD differs widely among those it affects, presenting challenges in social interaction and communication.

The double-blind, randomised and placebo-controlled study has been initiated at the Soroka Medical Center in Israel.

SCI-210 is a combination of cannabidiol (CBD) and SciSparc's Palmitoylethanolamide, designed to alleviate ASD symptoms.

SciSparc will enrol 60 subjects aged between five and 18 years over 20 weeks for scientifically measuring how the therapy compares to standard CBD treatment in managing symptoms of ASD.

SciSparc CEO Oz Adler said: “Our pioneering treatment aims to reduce and alleviate the symptoms of autism along with reducing the side effects that are common when taking cannabis-based treatments, such as CBD.

“Partnering with the Soroka Medical Center and the National Autism Research Center, we are exploring new territory in ASD treatment.

“We are driven by science and the goal of improving life quality for children with ASD and their families.”

During this month, SciSparc started a Phase IIb clinical study of SCI-110 to treat patients with Tourette Syndrome.

The study is being conducted under the regulation of the US Food and Drug Administration (FDA), the Israeli Ministry of Health, and the Federal Institute for Drugs and Medical Devices in Germany.

The company commenced the trial at the Tel Aviv Sourasky Medical Center and is anticipated to continue with its medical sites in Germany and the US.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close